Amphastar Pharmaceuticals Inc vs iShares MSCI Hong Kong ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while iShares MSCI Hong Kong ETF trades at $22.48. The key difference: iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | EWH | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $24.55 |
52-Week Low | $16.87 | $20.66 |
Enterprise Value | $1.26B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
EWH trades at $22.71 with a 0.98% daily gain, showing neutral technical signals overall. The ETF tracks Hong Kong equities, with recent momentum in the Hang Seng Index providing support. Moving averages indicate bullish momentum while oscillators remain neutral. The fund declared a $0.35 dividend payable in June 2026, offering income potential alongside capital appreciation.
Outlook remains balanced with technical strength offset by valuation concerns. Key opportunities include Hong Kong market recovery and technology sector momentum, while risks involve Asian market volatility and geopolitical tensions. The neutral technical stance suggests waiting for clearer directional signals before establishing new positions.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →